These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25470397)

  • 1. Cognitive dysfunction in depression - pathophysiology and novel targets.
    Carvalho AF; Miskowiak KK; Hyphantis TN; Kohler CA; Alves GS; Bortolato B; G Sales PM; Machado-Vieira R; Berk M; McIntyre RS
    CNS Neurol Disord Drug Targets; 2014; 13(10):1819-35. PubMed ID: 25470397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive remission: a novel objective for the treatment of major depression?
    Bortolato B; Miskowiak KW; Köhler CA; Maes M; Fernandes BS; Berk M; Carvalho AF
    BMC Med; 2016 Jan; 14():9. PubMed ID: 26801406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a "metabolic" subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction.
    Liu CS; Carvalho AF; McIntyre RS
    CNS Neurol Disord Drug Targets; 2014; 13(10):1693-707. PubMed ID: 25470395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder.
    McIntyre RS; Xiao HX; Syeda K; Vinberg M; Carvalho AF; Mansur RB; Maruschak N; Cha DS
    CNS Drugs; 2015 Jul; 29(7):577-89. PubMed ID: 26290264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive impairment in major depressive disorder.
    Pan Z; Park C; Brietzke E; Zuckerman H; Rong C; Mansur RB; Fus D; Subramaniapillai M; Lee Y; McIntyre RS
    CNS Spectr; 2019 Feb; 24(1):22-29. PubMed ID: 30468135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder.
    Pan Z; Grovu RC; Cha DS; Carmona NE; Subramaniapillai M; Shekotikhina M; Rong C; Lee Y; McIntyre RS
    CNS Neurol Disord Drug Targets; 2017; 16(8):891-899. PubMed ID: 28933261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review.
    Bortolato B; Carvalho AF; McIntyre RS
    CNS Neurol Disord Drug Targets; 2014; 13(10):1804-18. PubMed ID: 25470396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders.
    Peyrovian B; Rosenblat JD; Pan Z; Iacobucci M; Brietzke E; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():387-404. PubMed ID: 30738126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognition as a target in major depression: new developments.
    Solé B; Jiménez E; Martinez-Aran A; Vieta E
    Eur Neuropsychopharmacol; 2015 Feb; 25(2):231-47. PubMed ID: 25640673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target.
    Goeldner C; Ballard TM; Knoflach F; Wichmann J; Gatti S; Umbricht D
    Neuropharmacology; 2013 Jan; 64():337-46. PubMed ID: 22992331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothalamic-pituitary-adrenal axis activity and cognition in major depression: The role of remission status.
    Salvat-Pujol N; Labad J; Urretavizcaya M; de Arriba-Arnau A; Segalàs C; Real E; Ferrer A; Crespo JM; Jiménez-Murcia S; Soriano-Mas C; Menchón JM; Soria V
    Psychoneuroendocrinology; 2017 Feb; 76():38-48. PubMed ID: 27883963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Digging deeper in the differential effects of inflammatory and psychosocial stressors in remitted depression: Effects on cognitive functioning.
    Niemegeers P; de Boer P; Schuermans J; Dumont GJH; Coppens V; Spittaels K; Claes S; Sabbe BGC; Morrens M
    J Affect Disord; 2019 Feb; 245():356-363. PubMed ID: 30423462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega 3 Fatty Acids: Novel Neurotherapeutic Targets for Cognitive Dysfunction in Mood Disorders and Schizophrenia?
    Knöchel C; Voss M; Grüter F; Alves GS; Matura S; Sepanski B; Stäblein M; Wenzler S; Prvulovic D; Carvalho AF; Oertel-Knöchel V
    Curr Neuropharmacol; 2015; 13(5):663-80. PubMed ID: 26467414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition and Treatment of Cognitive Dysfunction in Major Depressive Disorder.
    Zuckerman H; Pan Z; Park C; Brietzke E; Musial N; Shariq AS; Iacobucci M; Yim SJ; Lui LMW; Rong C; McIntyre RS
    Front Psychiatry; 2018; 9():655. PubMed ID: 30564155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive dysfunction and work productivity in major depressive disorder.
    Clark M; DiBenedetti D; Perez V
    Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):455-63. PubMed ID: 27268275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential effect of herbal antidepressants on cognitive deficit: Pharmacological activity and possible molecular mechanism.
    Li JM; Zhao Y; Sun Y; Kong LD
    J Ethnopharmacol; 2020 Jul; 257():112830. PubMed ID: 32259666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions.
    McIntyre RS; Cha DS; Soczynska JK; Woldeyohannes HO; Gallaugher LA; Kudlow P; Alsuwaidan M; Baskaran A
    Depress Anxiety; 2013 Jun; 30(6):515-27. PubMed ID: 23468126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Social cognitive abilities predict psychosocial dysfunction in major depressive disorder.
    Knight MJ; Baune BT
    Depress Anxiety; 2019 Jan; 36(1):54-62. PubMed ID: 30211966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of randomized controlled trials of candidate treatments for cognitive impairment in depression and methodological challenges in the field.
    Miskowiak KW; Ott CV; Petersen JZ; Kessing LV
    Eur Neuropsychopharmacol; 2016 Dec; 26(12):1845-1867. PubMed ID: 27745932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin: repurposing opportunities for cognitive and mood dysfunction.
    Ying MA; Maruschak N; Mansur R; Carvalho AF; Cha DS; McIntyre RS
    CNS Neurol Disord Drug Targets; 2014; 13(10):1836-45. PubMed ID: 25470390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.